"EventusDx researchers have developed the Octava™ tests as the first in a new class of rapid, accurate and cost-effective blood tests that measure breast cancer-specific autoantibodies to detect the presence or absence of breast cancer. The Octava tests are designed to be used in conjunction with annual screening mammograms. They have been validated by clinical studies conducted at cancer centers in the U.S., Israel and Italy that analyzed blood samples from over 800 women. These women all had positive mammograms and their breast cancer pathologies were verified by biopsy.
An article reporting the results of a large clinical study of the Octava Blue test conducted in collaboration with researchers at the MD Anderson Cancer Center and other leading breast cancer specialists was recently published in the peer reviewed journal, Biomarkers in Cancer. The study assessed blood samples from more than 500 women who had positive mammograms followed by breast biopsy to definitively ascertain whether or not they had breast cancer. It showed that the Octava Blue test was accurate, correctly identifying the presence or absence of breast cancer with very high sensitivity and good specificity.
The Octava Blue test is designed for use in conjunction with screening mammograms to provide additional diagnostic information to help physicians confirm true abnormal mammography results with high accuracy, while also helping to reduce the large number of unnecessary biopsies caused by false positive results. False positive mammograms are common. Studies show that 80% of the biopsies performed after an abnormal mammography result are negative, indicating that no cancer is actually present. Octava Blue has the potential to help confirm true positive results and reduce the number of unneeded biopsies by up to 50%, saving many women the anxiety and invasiveness of the biopsy procedure while also reducing unnecessary medical costs."